Camillo Porta, MD, offers key takeaways from CheckMate 9ER trial in renal cell carcinoma
February 26th 2025"At ASCO GU, we presented the final analysis of the study, which confirmed the superiority of a combination over the TKI monotherapy in terms of both progression-free survival as well as overall survival," says Camillo Porta, MD.